title: Structurally differentiated cis-elements that interact with PU.1 are functionally distinguishable in acute promyelocytic leukemia.
abstract: BACKGROUND
  Transcription factor PU.1, a member of the ETS family, is a master regulator of myeloid differentiation whose functional disruption is often associated with acute myeloid leukemia (AML). Although much has been learned about PU.1 over the past decades, relatively little is known about cis-elements that interact with this factor under physiological or pathological conditions, especially in the whole-genome scale. We aimed to define the cistrome of PU.1 in acute promyelocytic leukemia (APL) cells and characterize the cis-elements bound by PU.1.
  
  
  METHODS
  Chromatin immunoprecipitation with specific antibody coupled with deep sequencing (ChIP-seq) was used to investigate the in vivo PU.1 binding sites at the whole-genome scale in APL-derived NB4 cells. The ChIP-quantitative (q)-PCR and luciferase reporter assays were used to validate the binding events and trans-activity, respectively. Various computational analyses, including motif mining, evolutionary conservation analysis and functional enrichment analysis, were performed to characterize the cis-elements that interacted with PU.1.
  
  
  RESULTS
  A total of 26,907 significantly enriched binding regions of PU.1 were identified under the false discovery rate 0.1% in NB4 cells. PU.1 bound to various types of genomic regions and acted as a promoter-enhancer dual binding transcription factor. Based on the sequence length and composition, two types of representative motifs were identified in PU.1 binding sites: a long and a short motif. The long motif, characterized by high sequence specificity and binding affinity, predominantly resided in the promoter-distal regions. In contrast, the short one, with strong evolutionary constraint, represented the primary PU.1 cis-elements in the promoter-proximal regions. Interestingly, the short one showed more preference to be correlated with the binding of other factors, especially PML/RARα. Moreover, genes targeted by both PU.1 and PML/RARα were significantly involved in categories associated with oncogenesis, hematopoiesis and the pathogenesis of acute myeloid leukemia.
  
  
  CONCLUSIONS
  Our results demonstrate that structurally differentiated cis-elements that interact with PU.1 are functionally distinguishable in APL, suggesting that the sequence diversity of cis-elements might be a critical mechanism by which cells interpret the genome, and contribute to distinct physiological and/or pathological function.
authors.affiliation: Institute of Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences CAS, Shanghai 200025, China.
authors.forename: Maoxiang
authors.initials: M
authors.lastname: Qian
authors.forename: Wen
authors.initials: W
authors.lastname: Jin
authors.forename: Xuehua
authors.initials: X
authors.lastname: Zhu
authors.forename: Xiaohong
authors.initials: X
authors.lastname: Jia
authors.forename: Xianwen
authors.initials: X
authors.lastname: Yang
authors.forename: Yanzhi
authors.initials: Y
authors.lastname: Du
authors.forename: Kankan
authors.initials: K
authors.lastname: Wang
authors.forename: Ji
authors.initials: J
authors.lastname: Zhang
mesh_terms: D001665:Binding Sites; D002454:Cell Differentiation; D047369:Chromatin Immunoprecipitation; D015894:Genome, Human; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000235:genetics*; D008156:Luciferases / Q000378:metabolism; D011485:Protein Binding; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D060888:Real-Time Polymerase Chain Reaction; D050436:Regulatory Elements, Transcriptional / Q000235:genetics*; D015534:Trans-Activators / Q000235:genetics*; D014157:Transcription Factors / Q000235:genetics*; D014407:Tumor Cells, Cultured; D000099232:Proto-Oncogene Protein Spi-1
chemical_list: D008156:Luciferases; D011518:Proto-Oncogene Proteins; D015534:Trans-Activators; D014157:Transcription Factors; D000099232:Proto-Oncogene Protein Spi-1
references.citation: Nat Rev Genet. 2011 Dec 06;13(1):59-69
references.pmid: 22143240
references.citation: PLoS One. 2011;6(9):e24576
references.pmid: 21931761
references.citation: Blood. 2006 Apr 15;107(8):3330-8
references.pmid: 16352814
references.citation: J Biol Chem. 1993 Mar 5;268(7):5014-20
references.pmid: 8095266
references.citation: BMC Genomics. 2005 Aug 17;6:110
references.pmid: 16107220
references.citation: Mol Cell Biol. 1993 May;13(5):2929-41
references.pmid: 8474451
references.citation: Science. 2008 Mar 28;319(5871):1793-4
references.pmid: 18369139
references.citation: Blood. 1998 Nov 15;92(10):3636-46
references.pmid: 9808557
references.citation: Cell. 2007 Mar 23;128(6):1231-45
references.pmid: 17382889
references.citation: Nucleic Acids Res. 2009 Jan;37(Database issue):D755-61
references.pmid: 18996895
references.citation: Cancer Res. 2007 May 15;67(10):5017-24
references.pmid: 17510434
references.citation: Nucleic Acids Res. 2009 Jul;37(Web Server issue):W202-8
references.pmid: 19458158
references.citation: Genome Res. 2012 Sep;22(9):1798-812
references.pmid: 22955990
references.citation: J Hematol Oncol. 2012 May 08;5:22
references.pmid: 22569057
references.citation: Mol Cell Biol. 2005 Apr;25(7):2832-45
references.pmid: 15767686
references.citation: Blood. 2002 Jun 15;99(12):4578-87
references.pmid: 12036891
references.citation: BMC Genomics. 2006 Oct 11;7:254
references.pmid: 17032459
references.citation: Cell. 2008 Mar 21;132(6):958-70
references.pmid: 18358809
references.citation: Nat Rev Genet. 2007 Mar;8(3):206-16
references.pmid: 17304246
references.citation: Cancer Cell. 2010 Feb 17;17(2):186-97
references.pmid: 20159610
references.citation: Nat Genet. 2004 Jun;36(6):624-30
references.pmid: 15146183
references.citation: Nat Rev Cancer. 2003 Feb;3(2):89-101
references.pmid: 12563308
references.citation: Nat Genet. 2006 Nov;38(11):1289-97
references.pmid: 17013392
references.citation: Mol Cell. 2009 Nov 25;36(4):682-95
references.pmid: 19941827
references.citation: Mol Cell Biol. 1994 Jan;14(1):373-81
references.pmid: 8264604
references.citation: Nature. 2012 Sep 6;489(7414):57-74
references.pmid: 22955616
references.citation: Cell. 1990 Apr 6;61(1):113-24
references.pmid: 2180582
references.citation: Hum Genet. 1990 May;84(6):542-6
references.pmid: 2338340
references.citation: Oncogene. 1995 Oct 19;11(8):1549-60
references.pmid: 7478579
references.citation: J Immunol. 2010 May 1;184(9):5018-28
references.pmid: 20363966
references.citation: Genome Res. 2008 Dec;18(12):1906-17
references.pmid: 18787082
references.citation: Genome Biol. 2008;9(9):R137
references.pmid: 18798982
references.citation: Proc Natl Acad Sci U S A. 2005 Aug 30;102(35):12513-8
references.pmid: 16113082
references.citation: Cell. 2005 Jul 15;122(1):33-43
references.pmid: 16009131
references.citation: Science. 2009 Jun 26;324(5935):1720-3
references.pmid: 19443739
references.citation: Mol Cell Biol. 1995 Oct;15(10):5830-45
references.pmid: 7565736
references.citation: J Immunol. 1999 Dec 1;163(11):6095-105
references.pmid: 10570299
references.citation: Cell. 2004 Feb 20;116(4):499-509
references.pmid: 14980218
references.citation: J Biol Chem. 1999 Nov 5;274(45):32453-60
references.pmid: 10542290
references.citation: Oncogene. 1996 Nov 7;13(9):1955-64
references.pmid: 8934542
references.citation: Stem Cells Dev. 2005 Apr;14(2):140-52
references.pmid: 15910240
references.citation: Nat Methods. 2007 Aug;4(8):651-7
references.pmid: 17558387
references.citation: Nature. 2012 Sep 6;489(7414):109-13
references.pmid: 22955621
references.citation: Blood. 1996 Aug 15;88(4):1234-47
references.pmid: 8695841
references.citation: Mol Cell. 2009 Nov 25;36(4):667-81
references.pmid: 19941826